Johnson & Johnson (JNJ) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Total Cash From Operating Activities Chart for Johnson & Johnson
Johnson & Johnson (JNJ) operating cash flow for FY2025 was USD 24.5B, a 1.1% change from FY2024. Johnson & Johnson's operating cash flow grew from USD 1.2B in 1989 to USD 24.5B in 2025 (1862.4% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of 0.8%, 10-year CAGR of 2.4%, 20-year CAGR of 3.7%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $635.56B
- Implied Share Price
- $263.73
- Enterprise Value
- $677.00B
- Revenue (TTM)
- $97.93B
- EBITDA
- $34.87B
- Profit Margin
- 21.48%
- Trailing P/E
- 30.81
- Forward P/E
- 21.01
- Price/Book (MRQ)
- 7.63
- Price/Sales (TTM)
- 6.49
- EV/EBITDA
- 19.94
- EV/Revenue
- 6.91
- Dividend Yield
- 2.00%
- Book Value
- $35.28
- Free Cash Flow (FY2025)
- $19.70B
- Free Cash Flow Yield
- 3.10%
Snapshot as of 13th October 2026 — not point-in-time controlled, may lag the live market by a few days.